dc.contributor | IDIAP Jordi Gol |
dc.contributor.author | Prat-Vallverdú, Oriol |
dc.contributor.author | Quijada-Manuitt, Mª Ángeles |
dc.contributor.author | Morros, Rosa |
dc.contributor.author | Giner-Soriano, Maria |
dc.contributor.author | Gomez-Lumbreras, Ainhoa |
dc.contributor.author | Cortés, Jordi |
dc.date.accessioned | 2020-08-14T07:12:40Z |
dc.date.available | 2020-08-14T07:12:40Z |
dc.date.issued | 2020-08-09 |
dc.identifier.citation | Giner-Soriano M, Cortés J, Gómez-Lumbreras A, Prat-Vallverdú O, Quijada-Manuitt MA, Morros R. The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: a real-world data cohort study. Aten Primaria. 2020:1-10. |
dc.identifier.issn | 0212-6567 |
dc.identifier.uri | https://hdl.handle.net/11351/5184 |
dc.description | Atrial fibrillation; Oral anticoagulants; Adherence; Persistence; Electronic health records |
dc.description.abstract | Objective: We aimed to describe sociodemographic, comorbidities, co-medication and risk of thromboembolic events and bleeding in patients with NVAF initiating oral anticoagulants (OAC) for stroke prevention, and to estimate adherence and persistence to OAC.
Setting: Primary Health Care (PHC) in the Catalan Health Institute (ICS), Catalunya, Spain.
Participants: All NVAF adult patients initiating OAC for stroke prevention in August 2013---December 2015.
Methods: Population-based cohort study. Persistence was measured in patients initiating OAC in August 2013---December 2014.
Data source: SIDIAP, which captures electronic health records from PHC in the (ICS), covering approximately 5.8 million people.
Results: 51,690 NVAF patients initiated OAC; 47,197 (91.3%) were naive to OAC and 32,404
(62.7%) initiated acenocoumarol. Mean age was 72.8 years (SD 12.3) and 49.4% were women.
Platelet-aggregation inhibitors were taken by 9105 (17.6%) of the patients. Persistence and adherence were estimated up to the end of follow-up. For 22,075 patients, persistence was higher among the non-naive patients [n = 258 (61.7%)] than among the naive [n = 11,502 (53.1%)].
Adherence was estimated for patients initiating DOAC and it was similar in naive and non-naive patients. Among the naive to DOAC treatment, those starting rivaroxaban showed a highest proportion [(n = 360 (80.1%)] of good adherence at implementation (MPR > 80%) while patients starting dabigatran were less adherent [n = 203 (47.8%)].
Conclusions: Acenocoumarol was the most frequently prescribed OAC as first therapy in NVAF patients. Non-naive to DOAC showed better persistence than naive. Rivaroxaban showed higher proportion of adherent patients during the implementation phase than apixaban and dabigatran the lowest. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Atención primaria; |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Farmacoepidemiologia |
dc.subject | Anticoagulants (Medicina) |
dc.subject | Fibril·lació auricular - Tractament - Catalunya |
dc.subject.mesh | Pharmacoepidemiology |
dc.subject.mesh | Anticoagulants |
dc.subject.mesh | Atrial Fibrillation |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Catalonia |
dc.title | The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: a real-world data cohort study |
dc.title.alternative | Uso y adherencia a los anticoagulantes orales en Atención Primaria en Cataluña, España: estudio de cohortes con datos procedentes de registros electrónicos de salud |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.aprim.2020.05.016 |
dc.subject.decs | farmacoepidemiología |
dc.subject.decs | anticoagulantes |
dc.subject.decs | fibrilación atrial |
dc.subject.decs | /tratamiento farmacológico |
dc.subject.decs | Cataluña |
dc.relation.publishversion | https://www.sciencedirect.com/science/article/pii/S0212656720301840?via%3Dihub |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Giner-Soriano M] Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Institut Català de la Salut, Generalitat de Catalunya, Barcelona, Spain. [Cortés J] Departament d’Estadística i Investigació Operativa, Universitat Politècnica de Catalunya, Barcelona, Spain. [Gómez-Lumbreras A] Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Departament de Ciències Mèdiques, Facultat de Medicina, Universitat de Girona, Girona, Spain. [Prat-Vallverdú O] Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Quijada-Manuitt MA] Department of Clinical Pharmacology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Department of Pathology and Experimental Therapeutics, Unitat Docent Campus de Bellvitge, Universitat de Barcelona, Barcelona, Spain. [Morros R] Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Institut Català de la Salut, Generalitat de Catalunya, Barcelona, Spain. UICEC IDIAP Jordi Gol, Plataforma SCReN, Barcelona, Spain |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |